Table 7. Incidence of Post-Challenge Symptoms on Days 42–49 by Dose: Pooled Data.
| Treatment Group | ||||
|---|---|---|---|---|
| Dose | Placebo | 15 μg x 2 | 30 μg x 1 | 30 μg x 2 |
| N | 45 | 19 | 43 | 38 |
| Efficacy Definition | n (%) | n (%) | n (%) | n (%) |
| Upper Respiratory Symptoms | 17 (37.8) | 1 (5.3) | 17 (39.5) | 7 (18.4) |
| Lower Respiratory Symptoms | 2 (4.4) | 0 | 4 (9.3) | 1 (2.6) |
| Systemic Symptoms | 17 (37.8) | 2 (10.5) | 9 (20.9) | 3 (7.9) |
| Fever | 9 (20.0) | 0 | 5 (11.6) | 0 |
| Any Symptoms | 21 (46.7) | 3 (15.8) | 18 (41.9) | 10 (26.3) |
| Seroconversion | 38 (84.4) | 6 (31.6) | 16 (37.2) | 5 (13.2) |
| Fever and Systemic Symptoms | 8 (17.8) | 0 | 4 (9.3) | 0 |
| Upper Respiratory and Systemic Symptoms | 14 (31.1) | 0 | 8 (18.6) | 0 |
| Fever and Upper Respiratory Symptoms | 7 (15.6) | 0 | 5 (11.6) | 0 |
| Seroconversion and Any Symptoms | 20 (44.4) | 2 (10.5) | 8 (18.6) | 3 (7.9) |
| Seroconversion and Systemic Symptoms | 16 (35.6) | 1 (5.3) | 4 (9.3) | 2 (5.3) |
| Seroconversion and Upper Respiratory Symptoms | 17 (37.8) | 1 (5.3) | 8 (18.6) | 1 (2.6) |
| Seroconversion and Fever | 9 (20.0) | 0 | 3 (7.0) | 0 |
| Seroconversion and (Lower Respiratory or Systemic Symptoms) | 16 (35.6) | 1 (5.3) | 5 (11.6) | 2 (5.3) |